Actinogen Medical Management
Management criteria checks 4/4
Actinogen Medical's CEO is Steve Gourlay, appointed in Mar 2021, has a tenure of 3.17 years. total yearly compensation is A$656.89K, comprised of 60.2% salary and 39.8% bonuses, including company stock and options. directly owns 3.63% of the company’s shares, worth €1.63M. The average tenure of the management team and the board of directors is 2.3 years and 6.4 years respectively.
Key information
Steve Gourlay
Chief executive officer
AU$656.9k
Total compensation
| CEO salary percentage | 60.2% |
| CEO tenure | 3.2yrs |
| CEO ownership | 3.6% |
| Management average tenure | 2.3yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$15m |
| Sep 30 2023 | n/a | n/a | -AU$13m |
| Jun 30 2023 | AU$657k | AU$396k | -AU$11m |
| Mar 31 2023 | n/a | n/a | -AU$11m |
| Dec 31 2022 | n/a | n/a | -AU$11m |
| Sep 30 2022 | n/a | n/a | -AU$10m |
| Jun 30 2022 | AU$955k | AU$376k | -AU$9m |
| Mar 31 2022 | n/a | n/a | -AU$8m |
| Dec 31 2021 | n/a | n/a | -AU$7m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$271k | AU$112k | -AU$4m |
Compensation vs Market: Steve's total compensation ($USD434.71K) is about average for companies of similar size in the German market ($USD389.95K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Gourlay (63 yo)
3.2yrs
Tenure
AU$656,888
Compensation
Dr. Steven G. Gourlay, also known as Steve, MBBS (M.D.), Ph D., FRACP, M.B.A., serves as Chief Executive Officer at Actinogen Medical Limited since March 15, 2021 and as its Managing Director and Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 3.2yrs | AU$656.89k | 3.63% A$ 1.6m | |
| Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 1.3yrs | AU$478.29k | no data | |
| Head of Clinical Pharmacology & Lead Physician and Depression | 2.3yrs | AU$191.66k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Head of Investor Relations & Corporate Communications | 3yrs | no data | no data | |
| Head of Manufacturing | less than a year | no data | no data | |
| Company Secretary | 10.6yrs | no data | no data |
2.3yrs
Average Tenure
63yo
Average Age
Experienced Management: 3AC's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 3.2yrs | AU$656.89k | 3.63% A$ 1.6m | |
| Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 2.3yrs | AU$478.29k | no data | |
| Independent Non-Executive Director | 6.4yrs | AU$118.33k | 0.44% A$ 199.2k | |
| Independent Non-Executive Chairman | 7.2yrs | AU$241.61k | 0.70% A$ 313.6k | |
| Member of Xanamem Clinical Advisory Board | 9.2yrs | no data | no data | |
| Member of Xanamem Clinical Advisory Board | 9.2yrs | no data | no data | |
| Independent Non-Executive Director | 5.1yrs | AU$118.33k | 0.27% A$ 119.3k | |
| Member of Depression & Cognition Clinical Advisory Board | 2.3yrs | no data | no data | |
| Chairman of Xanamem Clinical Advisory Board | 9.2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
6.4yrs
Average Tenure
70yo
Average Age
Experienced Board: 3AC's board of directors are considered experienced (6.4 years average tenure).